Sprecher DL - Search Results

1

Identification of a Human Whole Blood-Based Endothelial Cell Impedance Assay for Assessing Clinical Transient Receptor Potential Vanilloid 4 Target Engagement Ex Vivo.

Xu X, Goyal N, Costell MH, Roethke T, James CH, Thorneloe KS, Patterson J, Stoy P, Goodman K, Sprecher DL, Behm DJ. Xu X, et al. Among authors: sprecher dl. J Pharmacol Exp Ther. 2021 Mar;376(3):436-443. doi: 10.1124/jpet.120.000307. Epub 2020 Dec 29. J Pharmacol Exp Ther. 2021. PMID: 33376150

2

Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects.

Goyal N, Skrdla P, Schroyer R, Kumar S, Fernando D, Oughton A, Norton N, Sprecher DL, Cheriyan J. Goyal N, et al. Among authors: sprecher dl. Am J Cardiovasc Drugs. 2019 Jun;19(3):335-342. doi: 10.1007/s40256-018-00320-6. Am J Cardiovasc Drugs. 2019. PMID: 30637626 Clinical Trial.

3

Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial.

Stewart GM, Johnson BD, Sprecher DL, Reddy YNV, Obokata M, Goldsmith S, Bart B, Oughton A, Fillmore C, Behm DJ, Borlaug BA. Stewart GM, et al. Among authors: sprecher dl. Eur J Heart Fail. 2020 Sep;22(9):1641-1645. doi: 10.1002/ejhf.1809. Epub 2020 Mar 30. Eur J Heart Fail. 2020. PMID: 32227554 Free article. Clinical Trial.

4

Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire.

Mathias SD, Vallow S, Gipson DS, Thorneloe KS, Sprecher D. Mathias SD, et al. Am J Kidney Dis. 2017 Oct;70(4):532-540. doi: 10.1053/j.ajkd.2017.04.023. Epub 2017 Jun 26. Am J Kidney Dis. 2017. PMID: 28663063

5

Assessing the Impact of Losmapimod on Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis.

Gipson DS, Hladunewich MA, Lafayette R, Sedor JR, Rovin BH, Barbour SJ, McMahon A, Jennette JC, Nachman PH, Willette RN, Paglione M, Gao F, Ross Terres JA, Vallow S, Holland MC, Thorneloe KS, Sprecher DL. Gipson DS, et al. Among authors: sprecher dl. Kidney Int Rep. 2020 May 26;5(8):1228-1239. doi: 10.1016/j.ekir.2020.05.024. eCollection 2020 Aug. Kidney Int Rep. 2020. PMID: 32775822 Free PMC article.

6

Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.

Barbour AM, Sarov-Blat L, Cai G, Fossler MJ, Sprecher DL, Graggaber J, McGeoch AT, Maison J, Cheriyan J. Barbour AM, et al. Among authors: sprecher dl. Br J Clin Pharmacol. 2013 Jul;76(1):99-106. doi: 10.1111/bcp.12063. Br J Clin Pharmacol. 2013. PMID: 23215699 Free PMC article. Clinical Trial.

7

Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist.

Sprecher D, Maxwell M, Goodman J, White B, Tang CM, Boullay V, de Gouville AC. Sprecher D, et al. Eur J Pharmacol. 2015 Jun 5;756:1-7. doi: 10.1016/j.ejphar.2015.01.051. Epub 2015 Mar 12. Eur J Pharmacol. 2015. PMID: 25773497 Clinical Trial.

8

Correction to: Development of a conceptual model and patient-reported outcome measures for assessing symptoms and functioning in patients with heart failure.

Moshkovich O, Benjamin K, Hall K, Murphy R, von Maltzahn R, Gorsh B, Sikirica V, Saini R, Sprecher D. Moshkovich O, et al. Qual Life Res. 2020 Oct;29(10):2849. doi: 10.1007/s11136-020-02631-1. Qual Life Res. 2020. PMID: 32940849 Free PMC article.

9

A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.

Olson EJ, Mahar KM, Haws TF, Fossler MJ, Gao F, de Gouville AC, Sprecher DL, Lepore JJ. Olson EJ, et al. Among authors: sprecher dl. Clin Pharmacol Drug Dev. 2019 Oct;8(7):871-883. doi: 10.1002/cpdd.704. Epub 2019 Jul 3. Clin Pharmacol Drug Dev. 2019. PMID: 31268250 Clinical Trial.

10

Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.

Olson EJ, Pearce GL, Jones NP, Sprecher DL. Olson EJ, et al. Among authors: sprecher dl. Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2289-94. doi: 10.1161/ATVBAHA.112.247890. Epub 2012 Jul 19. Arterioscler Thromb Vasc Biol. 2012. PMID: 22814748 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

141 results

Search Page

Filters